The pivotal phase III KEYNOTE-426 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), Pfizer’s tyrosine kinase inhibitor, met both primary endpoints of overall survival and progression-free survival in the first-line treatment of advanced or metastatic renal cell carcinoma.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
